Revenue segments as reported by the company.

Online Revenue

Wholesale Revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing

Operations and support

Technology and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hims & Hers Health achieves record revenue and profitability growth

Hims & Hers Health shows strong financial performance with revenue growth and profitability milestones.
The company's focus on customer-centric strategies, brand building, and innovation drives growth.
Challenges include competition in new categories and maintaining margins on personalized products.
Opportunities lie in expanding product offerings, improving customer experience, and leveraging efficiencies.

Hims & Hers Health excels in Q1 earnings, eyes strategic growth

Hims & Hers Health delivered robust financial performance in Q1 2023, driven by revenue growth, improved margins, and disciplined expense management.
The company's strengths lie in its focus on trusted brands, innovation in product offerings, and commitment to clinical excellence, fostering consumer trust and loyalty.
While challenges like insurance reimbursement and new category entries exist, they present opportunities for strategic growth and market differentiation in the healthcare sector.

Hims & Hers Health (HIMS) reports robust Q2 earnings, eyes personalized healthcare growth

Hims & Hers Health delivered strong financial performance in Q2, driven by revenue growth, expanded gross margins, and operational efficiency. While facing short-term challenges from pricing investments, the company remains focused on long-term growth through personalized treatments and new category launches. Opportunities lie in leveraging consumer trends towards personalized healthcare and expanding product offerings.

Hims & Hers Health reports robust Q3 performance and growth opportunities

Hims & Hers Health (HIMS) showcased strong performance, innovation, and resilience in Q3, driving revenue growth, subscriber base expansion, and improved profitability.
While challenges like achieving positive net income and balancing growth with new category launches exist, the company's strategic initiatives and focus on customer value creation position it for future success.
Opportunities in the weight management category, personalized products, and efficiency gains present avenues for HIMS to capitalize on market trends and enhance its competitive edge.
With a solid financial position, a clear marketing strategy, and a commitment to customer engagement, HIMS is poised for continued growth and value creation in the healthcare sector.

Hims & Hers Health reports stellar Q4 performance and growth outlook

Hims & Hers Health delivered a strong performance in Q4 2023, with robust revenue growth, positive net income, and expanded gross margins.
The company's focus on personalized solutions, subscriber growth, and financial strength positions it well for future growth and market expansion.
While facing challenges in managing costs and margin expansion, HIMS has opportunities to drive revenue growth, enhance user experience, and offer a diverse product range.
By balancing its strengths, addressing challenges, and seizing opportunities, Hims & Hers Health is poised for continued success in the healthcare market.

Hims & Hers Health reports stellar Q1 results and eyes expansion

Hims & Hers Health's Q1 2024 performance reflects strong financial growth, driven by record subscriber numbers and revenue increase, underpinned by a strategic focus on personalized care and enhancing customer experience.
The company's strengths lie in their ability to drive consumer adoption through user-friendly solutions, capitalize on the rapid growth of the Hers segment, and maintain consumer confidence through strategic pricing initiatives.
While facing challenges in scaling operations and managing increased capital expenditures, HIMS has ample opportunities to expand their offerings, invest in new product categories, and drive further revenue growth through strategic pricing adjustments.

Hims & Hers Health posts stellar Q2 results, eyes revenue diversification

Hims & Hers Health (HIMS) reported impressive Q2 performance, with strong revenue growth and subscriber additions.
The company's strategic initiatives in weight management and sterile compounded medications position it for future success.
While facing challenges in data availability and market dynamics, Hims & Hers has opportunities for revenue diversification and enhanced customer engagement.

Hims & Hers Health (HIMS) reports stellar Q3 results and eyes growth through personalized healthcare

Hims & Hers Health's Q3 performance reflects strong revenue growth, subscriber expansion, and improved profitability, positioning the company for continued success.
While facing challenges in retention and operational efficiency, the company's strategic initiatives and market positioning offer opportunities for sustained growth and innovation.
With a focus on personalized healthcare solutions and social responsibility, Hims & Hers Health is well-positioned to capitalize on market opportunities and drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hims was founded in November 2017 after Andrew Dudum was called out by his sister for having dry skin and breakouts. After she ordered him expensive products to address his issues, Dudum realized that men don't have the same options as women when it comes to purchasing wellness products. 

Now with radiant skin, Andrew Dudum and Jack Abraham co-found HIMS as an Atomic (VC fund) portfolio company. The company initially sells hair loss treatments, biotin vitamins, shampoo, and erectile dysfunction treatments. 

The company raises $7 million in Series A from M/C Partners, SV Angel and Thrive Captial, putting its pre-money valuation at $13 million.

Hims raises $40 million in Series B led by IVP and Redpoint Ventures, putting its pre-money valuation at $160 million. 

Hims launches a women's brand, Hers. 

Hers offers telemedicine services, birth control, and non-prescription hair and skin-care products. 

The company partners with A-list couple Jennifer Lopez and Alex Rodriguez, who work with the company on the launch of new products. 

Hims raises $297 million in Series C funding led by DCM Ventures, NewView Capital, McKesson Ventures, putting its valuation at $1 billion.

Hims and Hers expands into virtual mental health services led by licensed professionals, with support groups available free of charge during the COVID-19 pandemic. 

The company now provides access to medical care and treatment for more than a dozen conditions with more than 50 products, and has facilitated 1 million medical visits through its telehealth platforms in 2019. 

Hims goes public through a merger with a blank-check company Oaktree Acquisition Corp at $1.6 billion valuation.

forhims.com/aboutus
forhims.com/investors
SEC
CNBC
Business Insider
Bloomberg
Crunchbase
Axios

CrowdStrike

Teladoc

The telehealth sector will effectively reshape the medical services market in 2024. As a hotbed for innovation, it's attracting investors with its potential in a burgeoning market.

The 3 Hottest Telehealth Stocks to Watch in 2024

Hims & Hers has been a poor performer, as it wasn't as profitable as many investors had hoped.

Hims & Hers Health: Faultless, Ready To Go Higher

Hims & Hers is a fast-growing telehealth company with a focus on subscriptions and prescriptions for chronic conditions. The company's expansion into the weight loss drugs category significantly increases its total addressable market and will drive future revenue growth. The stock is significantly undervalued compared to peers on a DCF or comparable multiples valuation. This gap may close if the company inflects into profitability as guided in 1H 2024.

Hims & Hers: New Weight Loss Category Is A Prescription For Explosive Growth And Upward Revisions

Hims & Hers Health has reported strong quarterly results and improved profits, leading to a stock snapback. The company is moving into AI-based medical services and weight loss management to address soaring costs. The stock is incredibly cheap trading at less than 2x sales while forecast to top 20% growth for years ahead.

Hims & Hers Health: Promising Catalysts To Drive Stock Higher

Hims & Hers Health raised its guidance once again when it reported its Q3 results. The company saw significant growth in subscribers, particularly in the mental health and women's health sectors. HIMS is one of the cheapest growth stocks around.

Hims & Hers Health Q3: The Cheapest Growth Stock Around

Roku

SentinelOne

SentinelOne keeps delivering cutting-edge tech and strong growth. Roku is an entrenched streaming leader with future growth ahead.

My 2024 Financial Resolution: Buying More of These 3 Stocks

Hims & Hers Health is a telemedicine company specializing in a variety of treatments. The company's unique subscription model has helped propel strong top-line growth and margin expansion.

1 Healthcare Stock to Buy Hand Over Fist Going Into 2024

AGNC Investment

Crocs

Domino's Pizza

Federated Hermes

Groupon

Gravity Co

Gray TV

JD.com

Kamada

Malibu Boats

Methanex

OneMain Hld

PayPal

Semrush Holdings

SpringWorks Therapeutics Inc

Tarsus Pharmaceuticals

Tecnoglass

Vanguard S&P 500 ETF

WD-40

Wabash National

In November, we welcomed 24 new analysts who published their first article on Seeking Alpha. This series highlights and welcomes these newcomers to our ranks of analysts who share their unique insights and perspectives as well as some of their top investing ideas. We've compiled all of their firsts here for your review and to showcase the new perspectives being offered on the platform.

Celebrating Seeking Alpha's New Analysts - November 2023 Edition

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today unveiled Weight Loss by Hims & Hers, a comprehensive and customizable clinical approach specifically designed to help people achieve their individual weight-loss goals. The company also announced that Craig Primack, MD, FACP, FAAP, FOMA, a pioneer in the field of clinical obesity medicine, has joined the company as SVP of Weight Management. The scienc.

Hims & Hers Launches Holistic Weight Loss Program to Break the Endless Cycle of Weight Gain and Loss

Hims & Hers Health exhibits similarities to previous "100 Bagger" stocks, which I believe the market has not noticed at all. I wanted to bring this to the forefront. The company has the potential to be a transformative force in healthcare, with accelerating top-line growth, expanding margins, and a sticky subscriber base. HIMS has strong fundamentals, including profitability potential, high gross margins, value-added services, strong sales growth, and a growing subscriber base.

Hims & Hers Health: What Would The Author Of 100 Baggers Say?

E-health and wellness platform operator Hims & Hers Inc. NASDAQ: HIMS reported a stellar quarter of growth. The company has expanded its medical offerings well beyond offering discrete erectile dysfunction (ED) medication and sexual health products.

Hims & Hers earnings highlight expanded personalized treatments

American Well Corporation

CVS Health

Doximity

The telehealth sector is undergoing a significant transformation, reshaping the traditional contours of medical service delivery. This innovation-driven domain is drawing attention from investors, as top telehealth stocks show potential in a rapidly expanding market.

5 Telehealth Stocks That Have Nothing But Upside

Palantir Technologies

Well-chosen stocks can help you build lasting wealth. Read on to see how you could profit from the AI boom, as well as the shift toward more personalized healthcare.

2 No-Brainer Stocks to Buy Right Now for Less Than $50

Aehr Test Systems

AST SpaceMobile

Ginkgo Bioworks Holdings

Enovix Corporation

Rocket Lab USA

Recursion Pharmaceuticals

Finding a great small-cap stock to buy isn't always easy. We know that, over the long run, small-cap stocks as a whole outperform large-cap cousins.

2024's Hidden Gems: 7 Small-Caps Set for Explosive Growth

Hims & Hers reported another strong quarter this month as its growth rate remains above 50%. The company raised its forecast for the year as well.

Is Hims & Hers Stock a Buy Now?

The consensus price target hints at a 70.2% upside potential for Hims & Hers Health, Inc. (HIMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 70.23% Upside in Hims & Hers Health, Inc. (HIMS): Here's What You Should Know

The company reported another good quarter and announced a buyback. Is HIMS stock a buy?

Is Hims & Hers Health Stock a Buy After Strong Earnings?

In today's note, we will discuss Hims & Hers' Q3 2023 report, wherein the company delivered a solid beat across the board. Rapid revenue growth combined with significant margin expansion is a powerful combination, and that's precisely what Hims & Hers is showcasing right now. Given HIMS' strong business and weak stock performance, I am getting more bullish on the stock. Read on to learn more.

Hims & Hers Q3 2023: Another Fantastic Quarter, We're Buying More

Hims & Hers Health, Inc. (NYSE:HIMS ) Q3 2023 Earnings Conference Call November 6, 2023 5:00 PM ET Company Participants Alice Lopatto - VP, IR Andrew Dudum - Co-Founder, Chairman & CEO Yemi Okupe - CFO Conference Call Participants Glen Santangelo - Jefferies Daniel Grosslight - Citigroup Jack Wallace - Guggenheim Securities Jailendra Singh - Truist Securities Allen Lutz - Bank of America Merrill Lynch George Hill - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Hims & Hers Third Quarter 2023 Earnings Conference Call.

Hims & Hers Health, Inc. (HIMS) Q3 2023 Earnings Call Transcript

Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.

Hims & Hers Health, Inc. (HIMS) Reports Q3 Loss, Tops Revenue Estimates

Shares of Hims & Hers Health Inc. HIMS, -3.09% rose more than 3% in the extended session Monday after the telehealth company narrowed its quarterly loss and raised its sales guidance for the year, saying its “personalized” health offerings are resonating with people. Hims lost $7.6 million, or 4 cents a share, in the third quarter, which met FactSet consensus and compared with a loss of $18.8 million, or 9 cents a share, in the third quarter of 2022.

Hims and Hers narrows loss, raises revenue guidance for the year

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today reported financial results for the third quarter ended September 30, 2023. “I am proud of the progress made across several of our key pillars in the third quarter which meaningfully moved Hims & Hers one step closer toward our vision of an accessible, personalized platform,” said Andrew Dudum, co-founder and CEO. “Personalization cont.

Hims & Hers Health, Inc. Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Outlook

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company,” NYSE: HIMS), the leading health and wellness platform, today announced that its Board of Directors has authorized a share repurchase program of up to $50 million of outstanding Class A common stock over the next two years. Hims & Hers intends to use the program to repurchase shares on a discretionary basis from time to time, subject to general business and market conditions and other investment.

Hims & Hers Health, Inc. Announces $50 Million Share Repurchase Program Authorization

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS), the leading health and wellness platform, today introduced MedMatch, a technology designed to transform healthcare by giving providers a more intelligent and informed way to deliver personalized care to patients with more effective and precise treatments and medications. Currently in Beta, MedMatch deploys artificial intelligence and machine learning against the expansive dataset at t.

Hims & Hers Introduces MedMatch, The Next Generation of Intelligent Diagnostic Services

While HIMS showcases robust performance, its ability to navigate and mitigate associated risks will be pivotal in securing its future success. Major risks revolve around customer service issues, rising customer acquisition costs, and potential challenges in retaining customers due to branding and personalization concerns. With a proactive approach to addressing customer concerns and fine-tuning its operational strategies, Hims & Hers has the potential to overcome these challenges and thrive in the telehealth market.

News for Hims & Hers Health Stock (HIMS)